• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 12, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS

Artificial Spleen to Treat Bloodstream Infections

Bioengineer by Bioengineer
March 31, 2013
in NEWS
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
 
The device will be used to treat bloodstream infections that are the leading cause of death in critically ill patients and soldiers injured in combat.
 
To rapidly cleanse the blood of pathogens, the patient's blood is mixed with magnetic nanobeads coated with a genetically engineered version of a human blood 'opsonin' protein that binds to a wide variety of bacteria, fungi, viruses, parasites, and toxins. It is then flowed through microchannels in the device where magnetic forces pull out the bead-bound pathogens without removing human blood cells, proteins, fluids, or electrolytes — much like a human spleen does. The cleansed blood then flows back to the patient.
 
"In just a few years we have been able to develop a suite of new technologies, and to integrate them to create a powerful new device that could potentially transform the way we treat sepsis," said Wyss founding director and project leader, Don Ingber, M.D., Ph.D. "The continued support from DARPA enables us to advance our device manufacturing capabilities and to obtain validation in large animal models, which is precisely what is required to enable this technology to be moved towards testing in humans."
 
The team will work to develop manufacturing and integration strategies for its core pathogen-binding opsonin and Spleen-on-a-Chip fluidic separation technologies, as well as a novel coating technology called "SLIPS," which is a super-hydrophobic coating inspired from the slippery surface of a pitcher plant that repels nearly any material it contacts. By coating the inner surface of the channels of the device with SLIPS, blood cleansing can be carried out without the need for anticoagulants to prevent blood clotting.
 
In addition to Ingber, the multidisciplinary team behind this effort includes Wyss core faculty and Harvard School of Engineering and Applied Science faculty member Joanna Aizenberg, Ph.D., who developed the SLIPS technology; Wyss senior staff member Michael Super, Ph.D., who engineered the human opsonin protein; and Mark Puder, M.D., Ph.D., Associate Professor of Pediatric Surgery at Boston Children's Hospital and Harvard Medical School who will be assisting with animal studies.
 

Story Source:

The above story is reprinted from materials provided by Wyss Institute.

Tags: Artificial Spleen
Share12Tweet8Share2ShareShareShare2

Related Posts

Linking Lung Cancer and Rheumatoid Arthritis Genomics

November 12, 2025

Reassessment of GPC3’s Role in Breast Cancer Progression

November 12, 2025

Outcomes in Extensive-Stage Small Cell Lung Cancer Treatment

November 12, 2025

Iain Couzin Named a “Highly Cited Researcher” for 2025

November 12, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    317 shares
    Share 127 Tweet 79
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    209 shares
    Share 84 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    140 shares
    Share 56 Tweet 35
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1306 shares
    Share 522 Tweet 326

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Linking Lung Cancer and Rheumatoid Arthritis Genomics

Reassessment of GPC3’s Role in Breast Cancer Progression

Outcomes in Extensive-Stage Small Cell Lung Cancer Treatment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.